Beyond Air (XAIR) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$7.7M

Revenue (quarter)

$1.8M

Revenue growth (year over year)

+0.45%

Gross profit (trailing twelve months)

$321,000.00

Gross margin

4.18%

Net income (trailing twelve months)

−$34.4M

Net income (quarter)

−$8.2M

Net income growth (year over year)

−0.94%

Net margin

−447.64%

Return on equity

−561.77%

EPS (trailing twelve months)

−$60.53

Book value per share

$2.77

P/E (trailing twelve months)

—

Price to book

0.72

Debt to assets

91.37%

Payout ratio

—

Dividend yield

—

Company profile

Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.

• Is Beyond Air (XAIR) profitable?

  No. Beyond Air reported a net loss of $34.4M over the trailing twelve months.

• How much revenue does Beyond Air (XAIR) make?

  Beyond Air generated $7.7M in revenue over the trailing twelve months, up 0.45% year over year.

• How do I buy stock in Beyond Air (XAIR)?

  XAIR trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.